Abstract
The world is seeking effective and safe weight-lowering drugs for centuries. LEAP2, acting on ghrelin and growth hormone secretagogue receptor, according to a study by Hageman et al.(1) in this issue of Cell Reports Medicine, found its way toward the next target of pharmacotherapy for obesity and related diseases.